ArticleTherapeutic advances in endocrinology and metabolism2026
Glucose-lowering therapy in diabetes of the exocrine pancreas: a real-world evidence analysis in a tertiary hospital in the timeframe 2018-2022.
Article in Therapeutic advances in endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetes of the exocrine pancreas (DEP) is a form of diabetes that arises in the presence of an exocrine pancreas disease and is mainly associated with acute and chronic pancreatitis. Therapeutic management of DEP has not changed over the past decades, and treatment is mostly insulin based. However, type 2 diabetes (T2D) treatment guidelines have changed with the aim of normalizing glucose levels and preventing diabetes-related comorbidities. Objectives: The aim of this study was to evaluate real-word practice in the treatment of diabetes associated with pancreatitis, with a focus on individuals who had already developed cardiovascular and/or renal diseases. Designs: We conducted a cross-sectional observational study on adult patients admitted to a tertiary-level hospital in Italy between 2018 and 2022 with a prevalent diagnosis of pancreatitis and diabetes. Methods: Disease-related real-world data were collected from Hospital Information Systems using automated data extraction strategies and through the implementation of a patient-centered data repository. A multiple source real-world evidence-based methodology was used to identify patients with diabetes and to investigate changes in glucose-lowering treatments through hospitalizations. Results: We identified 2146 hospitalized patients with pancreatitis from 2018 to 2022, 675 (31.4%) of whom also had diabetes. Data on glucose-lowering therapies were available for 444 of these patients. Individuals with diabetes and pancreatitis were predominantly male (65.2%) and older than those without diabetes ( Conclusion: This real-world study provides updated evidence on the treatment of diabetes associated with pancreatitis in a tertiary care setting, showing a predominant use of insulin and metformin regardless of comorbidities. Despite emerging evidence on the benefits of non-insulin therapies in T2D, such approaches are not yet reflected in the management of DEP, underlining the need for specific clinical guidelines and dedicated trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.